The University of Iowa

Publications

Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology

Merit Cudkowicz, MD, MSc; Marianne K. Chase, BA; Christopher S. Coffey, PhD; Dixie J. Ecklund, RN, MSN, MBA; Brenda J. Thornell, BA; Codrin Lungu, MD; Katy Mahoney, BS; Laurie Gutmann, MD; JeremyM. Shefner,MD, PhD; Kevin J. Staley, MD; Michael Bosch, RN; Eric Foster, PhD; Jeffrey D. Long, PhD; Emine O. Bayman, PhD; James Torner, PhD; Jon Yankey, MS; Richard Peters, BS; Trevis Huff, BSE; Robin A. Conwit, MD; and the NeuroNEXT Clinical Study Sites.
JAMA Neurology. 2020 March 23; 755-763.
PubMed: 
32202612

Clinical and dopamine transporter imaging characteristics of leucine-rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson's Disease participants in the Parkinson's Progression Markers Initiative: A cross sectional study.

Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay R, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman S, Marek on behalf of the Parkinson's Progression Markers Initiative Investigators.
Movement Disorders. 2020 Feb 19; 35 (5) 833-844.
PubMed: 
PMC7231646

Improving natural product research translation: From source to clinical trial.

Sorkin BC, Kuszak AJ, Fukagawa NK, Hoffman FA, Jafari m, Barrett B, Brown PN, Bushman FD, Casper S, Chilton FH, Coffey CS, Ferruzi MG, Hopp DC, Kiely M, Lakens D, MacMillan JB, Meltzer DO, Pahor M, Paul J, Pritchett-Corning K, Quinney SK, Rehermann B, Setchell K, Sipes NS, Stephens JM, Taylor DL, Tiriac H, Walters WA, Xi D, Zappala G, Pauli GF.
FASEB Journal. 2019 Dec 10; 34 (1) 41-65.
PubMed: 
PMC7470648

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): A cross sectional study.

Simuni T, Uribe L, Cho RH, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun-Turgut D, Poston K, Poewe W, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman, Marek K, on behalf of the PPMI Investigators.
Lancet Neurology. 2019 October 31; 19 (1) 71-80.
PubMed: 
PMC6956652

Feasibility and safety of lumbar puncture in the Parkinson's Disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey CS, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Simuni T, on behalf of the Parkinson's Progression Markers Initiative Steering Committee, Study Cores, Site Investigators, Coordinators, and Industry & Scientific Advisory Board.
Parkinsonism & Related Disorders. 2019 May; 62 201-209.
PubMed: 
30738748